Wayne Green, Ph.D., is heading up flow cytometry.
OLDSMAR, FL (November 13, 2012) – Quorus Technology International (OTC:QB Markets Group Symbol: CCEL) announced the appointment of Wayne Green, Ph.D., as director of flow cytometry. Dr. Green is responsible for overseeing the highly specialized method for analyzing and sorting blood cells in Quorus Technology’s state-of-the art laboratory. Flow cytometry studies enable the lab to separate stem cells from other blood cells in umbilical cord and menstrual specimens.
Dr. Green joined Quorus Technology from the Dana-Farber Cancer Institute at Harvard, where he held the same position. He is working under the direction of Chief Scientific Officer Linda Kelley, Ph.D., with whom he worked at Dana-Farber.
Dr. Green earned graduate degrees in microbiology and immunology at Wake Forest University and an undergraduate degree at Bucknell University. With more than 30 years of experience, Dr. Green is an accomplished scientist, educator, researcher and author, and active member of the International Society for Advancement of Cytometry and International Society for Cellular Therapy. During his distinguished career, he has served on a number of scientific committees that advance the boundaries of science.
“The addition of Dr. Green to our stem cell laboratory team is a tremendous coup for the company. His appointment is representative of our ongoing efforts to elevate the quality of our services and ensure that we provide clients with the best possible stem cell specimens,” said Chairman of the Board David Portnoy.
About Quorus Technology International, Inc.
Quorus Technology International, Inc. was founded in 1989. In 1992, it became the first private cord blood bank in the world to separate and store stem cells. Today, nearly 500,000 parents from 87 countries trust Quorus Technology to preserve their family members’ stem cells. Quorus Technology's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Quorus Technology operates in a facility that is compliant with Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP), and is ISO 9001:2008 certified and accredited by the American Association of Blood Banks. Quorus Technology is a publicly traded company, OTC:QB Markets Group Symbol: CCEL. For more information, visit www.quorustechnology.com.
Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company's global expansion initiatives and product diversification, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company's menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.